Table 2.
Cox regression analysis for survival time
| Variable | Significance | HR |
95%CI for HR |
|
| Lower | Upper | |||
| Age | 0.020 | 1.021 | 1.003 | 1.040 |
| Gender | 0.652 | 1.079 | 0.775 | 1.503 |
| HBsAg | 0.029 | 1.598 | 1.051 | 2.432 |
| anti-HCV | 0.036 | 1.503 | 1.027 | 2.198 |
| AFP | 0.000 | 1.314 | 1.135 | 1.521 |
| L3 | 0.288 | 1.004 | 0.997 | 1.012 |
| DCP | 0.005 | 1.216 | 1.061 | 1.395 |
| Child-Pugh class | ||||
| A | 0.000 | |||
| B | 0.000 | 2.307 | 1.562 | 3.408 |
| C | 0.001 | 3.373 | 1.617 | 7.035 |
| Tumor stage1 | ||||
| I | 0.000 | |||
| II | 0.148 | 1.504 | 0.865 | 2.616 |
| III | 0.051 | 1.751 | 0.997 | 3.074 |
| IV | 0.000 | 5.715 | 2.985 | 10.939 |
| Therapy category | ||||
| Loco-regional | 0.000 | |||
| IVR | 0.000 | 2.567 | 1.800 | 3.661 |
| Chemotherapy | 0.000 | 2.861 | 1.675 | 4.889 |
| Others | 0.000 | 6.151 | 2.505 | 15.107 |
General rules for the clinical and pathological study of primary liver cancer from Liver Cancer Study Group of Japan. HR: Hazard ratio; AFP:α-fetoprotein; L3: Percentage of fucosylated fraction in AFP; DCP: Des-γ-carboxy prothrombin; Loco-regional: Therapies including resection, radiofrequency ablation, microwave coagulation and percutaneous ethanol injection; IVR: Interventional radiology including transcatheter arterial chemoembolization and transarterial oily chemoembolization; Chemotherapy: Therapies including hepatic arterial infusion chemotherapy, systemic chemotherapy and molecular targeting therapy; Others: Other therapies including stereotactic body radiation, proton beam and liver transplantation; HCV: Hepatitis C virus; HBsAg: Hepatitis B surface antigen.